Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Inhaled NO Therapy for Prevention of Nosocomial Pneumonia After Cardiac Surgery
NCT06261827Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Randomised, double-blind trial of nitric oxide in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoint: Incidence of nosocomial pneumonia. Started Feb 2024; status: completed.
02
Drugs
nitric oxide
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT06261827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261827.